Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog

Sleep

Volumn 26, Issue 8, 2003, Pages 953-959

  Fujiki, Nobuhiro ^a   Yoshida, Yasushi ^a   Ripley, Beth ^a   Mignot, Emmanuel ^a   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Canine narcolepsy; Cataplexy; Hypocretin; ICV; Narcolepsy; Orexin

Indexed keywords

DRUG RECEPTOR; OREXIN; OREXIN 2 RECEPTOR; OREXIN A; UNCLASSIFIED DRUG; CARRIER PROTEIN; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; OREXIN RECEPTORS; OREXINS; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CATAPLEXY; CONTROLLED STUDY; DOG; DRUG EFFECT; GENE MUTATION; MALE; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; SLEEP; WAKEFULNESS; ANIMAL; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; POINT MUTATION;

ANIMALS; BRAIN; CARRIER PROTEINS; CATAPLEXY; DOGS; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; INJECTIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; POINT MUTATION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 1642382070     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/26.8.953     Document Type: Article

References (24)

1. Nishino S, Okura M, Mignot E. Narcolepsy: Genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99.
2. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
3. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
4. Lin L, Faraco J, Li R, Kadotani H, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76.
5. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
6. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
7. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8:525-34.
8. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000;3:23-8.
9. Shiba T, Ozu M, Yoshida Y, Mignot E, Nishino S. Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate. Biochem Biophys Res Commun 2002;294:615-20.
10. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001;11:531-9.
11. Lim RKS, Liu C-N, Moffitt RL. A Stereotaxic Atlas of the Dog's Brain. Springfield, Ill: Thomas Books; 1960.
12. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain. implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15:4806-14.
13. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. JPET 1999;289:219-23.
14. Yoshida Y, Fujuki N, Maki R, Schwarz D, Nishino S. Differential kinetics of hypocretins in the CSF after intracerebroventricular administration in rats Neurosci Lett 2003;346:182-6
15. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats Eur J Neurosci 2000;12:726-30
16. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat Proc Natl Acad Sci U S A. 1999;96:10911-6
17. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995;18:817-26.
18. Horvath TL, Peyron C, Sabrina D et al Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 1999;415:145-9
19. Kodama T, Kimura M. Arousal effects of orexin-A correlate with GLU release from the locus coeruleus in rats. Peptides 2001;23:1673-81.
20. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons J Neurosci 2000;20:7760-5.
21. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25.
22. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38:715-30.
23. Baker TL, Foutz AS, McNerney V, Mitler MM, Dement WC. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol 1982;75:729-42.
24. Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 2001;142:3324-31.